Ion Cristobal-rekin lankidetzan egindako argitalpenak (8)

2020

  1. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

    Molecular Cancer Therapeutics, Vol. 19, Núm. 8, pp. 1696-1707

  2. The hippo pathway transducers yap1/tead induce acquired resistance to trastuzumab in her2-positive breast cancer

    Cancers, Vol. 12, Núm. 5

2018

  1. Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models

    Current Medicinal Chemistry, Vol. 25, Núm. 17, pp. 1976-1998

2017

  1. CIP2A confirms its prognostic value in triple-negative breast cancer

    Oncogene

2016

  1. C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer

    Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790

  2. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

    American Journal of Cancer Research, Vol. 6, Núm. 11, pp. 2661-2678

  3. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

    British Journal of Cancer, Vol. 115, Núm. 3, pp. 322-331

2015

  1. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

    Oncotarget, Vol. 6, Núm. 6, pp. 4299-4314